Government-Owned Inventions; Availability for Licensing, 19855 [2024-05880]
Download as PDF
<![CDATA[
19855
Federal Register / Vol. 89, No. 55 / Wednesday, March 20, 2024 / Notices
Resources/inputs
Identified via proposal ......
Activities
5. Assess feasibility of establishing priority
EPHS functions.
Enhanced Stability and Efficacy of
Pfs48/45 Domain III Protein Variants
for Malaria Vaccine Development Using
SPEEDesign Technology
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Description of Technology
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Peter Tung at 240–669–5483 or
peter.tung@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852: tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
Licensing information and copies of
the patent applications listed below may
be obtained by communicating with the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852 by
contacting Peter Tung at 240–669–5483
or peter.tung@nih.gov. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished patent applications related
to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
The technology includes modifying
the Plasmodium falciparum Pfs48/45
Domain III protein sequence to enhance
its stability and efficacy to aid in
malaria vaccine development. This
approach successfully overcomes
previous production challenges by
increasing the thermostability of the
antigen and eliminating the need for
additional modifications that could
impair vaccine effectiveness. Crucially,
the technology maintains the essential
neutralizing epitope of Pfs48/45,
ensuring its effectiveness in preventing
malaria transmission as a transmissionblocking vaccine. Developed using the
SPEEDesign program, these novel
protein variants show increased stability
and a more robust transmission blocking
response than wild-type proteins. The
potential applications of this technology
are providing a more stable and effective
vaccine, potentially reducing the
incidence of malaria and leading to
improved health outcomes.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• This malaria vaccine technology
offers competitive advantages by
providing increased thermostability and
enhanced immune response without the
need for efficacy-reducing
modifications, potentially
revolutionizing malaria prevention with
more effective and stable vaccine
options.
Competitive Advantages
• The development of more effective
and stable malaria vaccines offers
improved prevention strategies in
regions affected by this disease and
significantly contributing to global
health initiatives.
Development Stage
Pre-Clinical
Inventors: Niraj Tolia, Ph.D., Thayne
Dickey, Ph.D., all of NIAID.
VerDate Sep<11>2014
16:52 Mar 19, 2024
Jkt 262001
PO 00000
Frm 00060
Outcomes
Selection and testing of at least one pilot
program or demonstration project addressing the selected EPHS.
BILLING CODE 4166–14–P
[FR Doc. 2024–05826 Filed 3–19–24; 8:45 am]
khammond on DSKJM1Z7X2PROD with NOTICES
Outputs
Fmt 4703
Sfmt 4703
Improved capacity to develop and/or offer
public health programs and services to
address prioritized public health activities
in AI/AN communities.
Publications
Intellectual Property: HHS Reference
No. E–030–2023–0–US–01, US
Provisional Application No. 63/476,897,
filed on December 22, 2022; HHS
Reference No. E–030–2023–0–PC–01,
PCT Application No. PCT/US2023/
085849, filed on December 22, 2023
Licensing Contact: To license this
technology, please contact Peter Tung at
240–669–5483 or peter.tung@nih.gov,
and reference E–030–2023.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. For
collaboration opportunities, please
contact Peter Tung at 240–669–5483 or
peter.tung@nih.gov.
Dated: March 14, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2024–05880 Filed 3–19–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Manufacturing of AntiMalaria Monoclonal Antibody L9LS in
Transgenic Cows and Sheep
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this Notice to Taurgen
Malaria, Inc. (‘‘Taurgen’’),
headquartered in Logan, UT. Taurgen
Malaria, Inc. is a wholly-owned
subsidiary of Taurgen Therapeutics,
LLC, which is also headquartered in
Logan, UT.
SUMMARY:
E:\FR\FM\20MRN1.SGM
20MRN1
]]>Agencies
[Federal Register Volume 89, Number 55 (Wednesday, March 20, 2024)]
[Notices]
[Page 19855]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-05880]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Tung at 240-669-5483 or
[email protected]. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
Licensing information and copies of the patent applications listed
below may be obtained by communicating with the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852 by
contacting Peter Tung at 240-669-5483 or [email protected]. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants
for Malaria Vaccine Development Using SPEEDesign Technology
Description of Technology
The technology includes modifying the Plasmodium falciparum Pfs48/
45 Domain III protein sequence to enhance its stability and efficacy to
aid in malaria vaccine development. This approach successfully
overcomes previous production challenges by increasing the
thermostability of the antigen and eliminating the need for additional
modifications that could impair vaccine effectiveness. Crucially, the
technology maintains the essential neutralizing epitope of Pfs48/45,
ensuring its effectiveness in preventing malaria transmission as a
transmission-blocking vaccine. Developed using the SPEEDesign program,
these novel protein variants show increased stability and a more robust
transmission blocking response than wild-type proteins. The potential
applications of this technology are providing a more stable and
effective vaccine, potentially reducing the incidence of malaria and
leading to improved health outcomes.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
This malaria vaccine technology offers competitive
advantages by providing increased thermostability and enhanced immune
response without the need for efficacy-reducing modifications,
potentially revolutionizing malaria prevention with more effective and
stable vaccine options.
Competitive Advantages
The development of more effective and stable malaria
vaccines offers improved prevention strategies in regions affected by
this disease and significantly contributing to global health
initiatives.
Development Stage
Pre-Clinical
Inventors: Niraj Tolia, Ph.D., Thayne Dickey, Ph.D., all of NIAID.
Publications
Intellectual Property: HHS Reference No. E-030-2023-0-US-01, US
Provisional Application No. 63/476,897, filed on December 22, 2022; HHS
Reference No. E-030-2023-0-PC-01, PCT Application No. PCT/US2023/
085849, filed on December 22, 2023
Licensing Contact: To license this technology, please contact Peter
Tung at 240-669-5483 or [email protected], and reference E-030-2023.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Peter Tung at 240-669-5483 or
[email protected].
Dated: March 14, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-05880 Filed 3-19-24; 8:45 am]
BILLING CODE 4140-01-P
